Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$263K Buy
2,666
+21
+0.8% +$2.03K 0.01% 338
2026
Q1
$256K Sell
2,645
-1,608
-38% -$186K 0.01% 301
2025
Q4
$475K Buy
4,253
+33
+0.8% +$3.78K 0.01% 220
2025
Q3
$472K Sell
4,220
-13
-0.3% -$1.55K 0.01% 206
2025
Q2
$510K Sell
4,233
-3
-0.1% -$363 0.02% 196
2025
Q1
$493K Buy
4,236
+16
+0.4% +$1.95K 0.02% 191
2024
Q4
$506K Hold
4,220
0.02% 188
2024
Q3
$449K Sell
4,220
-4
-0.1% -$396 0.02% 194
2024
Q2
$399K Sell
4,224
-125
-3% -$13K 0.02% 200
2024
Q1
$481K Sell
4,349
-2
-0% -$187 0.02% 203
2023
Q4
$377K Sell
4,351
-6
-0.1% -$455 0.02% 219
2023
Q3
$306K Sell
4,357
-12
-0.3% -$835 0.02% 220
2023
Q2
$291K Hold
4,369
0.01% 227
2023
Q1
$258K Hold
4,369
0.01% 234
2022
Q4
$205K Buy
+4,369
New +$183K 0.01% 260

Other funds holding ESAB

Aspiriant LLC's ESAB Position: Q2 2026 in Review

Aspiriant LLC increased its ESAB (ESAB) stake by 0.79% in Q2 2026, buying an estimated $2.03K and bringing the position to 2,666 shares worth $263K. The position accounts for 0.01% of the portfolio, ranked #338.

Aspiriant LLC first reported a position in ESAB in Q4 2022 and has held it in 15 quarters since. The position peaked at $510K in Q2 2025. 48 funds tracked by Wall St. Rank hold ESAB as of Q2 2026.

  • Aspiriant LLC held 2,666 shares of ESAB worth $263K as of Q2 2026.
  • Aspiriant LLC bought 21 ESAB shares in Q2 2026, an estimated $2.03K.
  • ESAB made up 0.01% of Aspiriant LLC's portfolio in Q2 2026, its #338 holding.
  • Aspiriant LLC first reported a position in ESAB in Q4 2022 and has held it in 15 quarters since.
  • Aspiriant LLC's ESAB position peaked at $510K in Q2 2025.
  • 48 funds tracked by Wall St. Rank held ESAB as of Q2 2026.

Based on Aspiriant LLC's 13F filing for Q2 2026, filed 20 Jul 2026.